VanEck Pharmaceutical ETF News

Sector ETF report for PPH

The pharmaceuticals industry got a boost last year when a Covid-19 vaccine was introduced, but artificial intelligence (AI) could keep the sector and ETFs like the VanEck Vectors Pharmaceutical ETF (P

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

Sector ETF report for PPH

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,

Pharmaceutical stocks gained a lot from the pandemic and the race to vaccines, but most of that upside is off the table now. The post 7 Pharmaceutical Stocks That Could Get a Covid Hangover appeared f

Coming off a vaccine rally that started in the middle of 2020, the pharmaceutical industry will continue to evolve as technological advances make their way into the sector, which should help ETFs like

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

With 2020 election season in the rearview mirror, it could be a great time to revisit health and pharmaceutical ETFs, including the VanEck Vectors Pharmaceutical ETF (NASDAQ: PPH). PPH tracks the MVIS

By VanEck Hope Springs Eternal Hopes of a return to normality are increasing after a year of pandemic-induced tumult. News that COVID-19 vaccines developed by Pfizer and BioNTech, and Moderna were mor